Gevo Stock Forecast, Price & News

Gevo (NASDAQ:GEVO) Frequently Asked Questions

Is Gevo a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gevo in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gevo stock.
View analyst ratings for Gevo or view top-rated stocks.

How has Gevo's stock been impacted by Coronavirus (COVID-19)?

Gevo's stock was trading at $0.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GEVO stock has increased by 290.6% and is now trading at $3.75.
View which stocks have been most impacted by COVID-19.

Are investors shorting Gevo?

Gevo saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 36,390,000 shares, an increase of 16.4% from the December 15th total of 31,250,000 shares. Based on an average daily volume of 8,370,000 shares, the short-interest ratio is currently 4.3 days. Currently, 18.7% of the company's shares are sold short.
View Gevo's Short Interest.

When is Gevo's next earnings date?

Gevo is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Gevo.

How were Gevo's earnings last quarter?

Gevo, Inc. (NASDAQ:GEVO) announced its earnings results on Wednesday, November, 10th. The energy company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The energy company earned $0.14 million during the quarter, compared to analysts' expectations of $0.27 million. Gevo had a negative trailing twelve-month return on equity of 10.81% and a negative net margin of 5,113.13%. During the same period in the prior year, the company earned ($0.08) EPS.
View Gevo's earnings history.

When did Gevo's stock split? How did Gevo's stock split work?

Shares of Gevo reverse split on the morning of Monday, June 4th 2018. The 1-20 reverse split was announced on Friday, June 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 1st 2018. An investor that had 100 shares of Gevo stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for GEVO?

2 Wall Street analysts have issued 1-year price targets for Gevo's shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Gevo's share price to reach $14.67 in the next year. This suggests a possible upside of 291.1% from the stock's current price.
View analysts' price targets for Gevo or view top-rated stocks among Wall Street analysts.

Who are Gevo's key executives?

Gevo's management team includes the following people:

• Patrick R. Gruber, Chief Executive Officer & Director
• Christopher Michael Ryan, President & Chief Operating Officer
• Lynn Lynn Smull, Chief Financial Officer
• Geoffrey T. Williams, Secretary, Vice President & General Counsel
• Alisher Nurmat, Vice President & Controller

What is Patrick Gruber's approval rating as Gevo's CEO?

7 employees have rated Gevo CEO Patrick Gruber on Glassdoor.com. Patrick Gruber has an approval rating of 15% among Gevo's employees. This puts Patrick Gruber in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gevo's key competitors?

Some companies that are related to Gevo include Marathon Petroleum (MPC), Phillips 66 (PSX), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), CVR Energy (CVI), PBF Energy (PBF), Green Plains (GPRE), World Fuel Services (INT), Amyris (AMRS), Clean Energy Fuels (CLNE), Delek US (DK), REX American Resources (REX) and Adams Resources & Energy (AE).
View all of GEVO's competitors.

What other stocks do shareholders of Gevo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gevo investors own include Bionano Genomics (BNGO), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Denison Mines (DNN), Novan (NOVN) and CBL & Associates Properties (CBL).

What is Gevo's stock symbol?

Gevo trades on the NASDAQ under the ticker symbol "GEVO."

Who are Gevo's major shareholders?

Gevo's stock is owned by a number of institutional and retail investors. Top institutional investors include Cutler Group LP (0.00%).
View institutional ownership trends for Gevo.

Which major investors are selling Gevo stock?

GEVO stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Gevo or view top insider-selling stocks.

How do I buy shares of Gevo?

Shares of GEVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gevo's stock price today?

One share of GEVO stock can currently be purchased for approximately $3.75.

How much money does Gevo make?

Gevo has a market capitalization of $756.98 million and generates $5.54 million in revenue each year. The energy company earns $-40.19 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Gevo have?

Gevo employs 32 workers across the globe.

What is Gevo's official website?

The official website for Gevo is www.gevo.com.

Where are Gevo's headquarters?

Gevo is headquartered at 345 Inverness Drive South Building C Suite 310, Englewood CO, 80112.

How can I contact Gevo?

Gevo's mailing address is 345 Inverness Drive South Building C Suite 310, Englewood CO, 80112. The energy company can be reached via phone at (303) 858-8358 or via email at [email protected].